August 28, Company Update Commerzbank Sector Conference Week

Transcription

1 August 28, 2012 Company Update Commerzbank Sector Conference Week

2 Safe Harbour This presentation includes forward-looking statements. Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties including changes in business, economic competitive conditions, regulatory reforms, foreign exchange rate fluctuations and the availability of financing. These and other risks and uncertainties are detailed in the Company s Annual Report. 2

3 Components of the Business Technology-driven Alliances Proven HuCAL platform Novel Slonomics and Ylanthia technologies provide new opportunities Innovative Product Pipeline MOR103 phase 1b/2a data coming soon Four partner phase 2 studies complete in clinical programs AbD Serotec Emerging diagnostics business Research antibody catalog Financially Strong Sustainably cash-flow positive Strong balance sheet 3

4 Technology-driven Alliances 4

5 Proprietary Technology Platform Underpins Lucrative Alliances MorphoSys has successfully partnered its human antibody technology HuCAL with many of the leading pharmaceutical companies Lucrative model Makes MOR cash-flow positive Funds proprietary R&D Future upside from milestones & royalties Target MorphoSys Pharma partner HuCAL antibody drug candidate R&D funding Technology licence fees Milestones and royalties 5

6 Case Study: MorphoSys-Novartis One of the largest discovery alliances in the industry Term Through 2017, plus 2-year extension option Novartis pays Approx. 20m p.a. technology license fees Approx. 20m p.a. research funding Milestones and royalties on all resulting drugs Novartis gets Codevelopment option Excluded Preferred access to HuCAL for use in over 100 discovery programs Shared costs & profits (20% 50%) on codeveloped programs Most infectious disease targets 6

7 New Technologies Drive New Deals Slonomics Best technology for making protein libraries Exclusive access secured through acquisition of Sloning Biotechnology in 2010 Deals have already paid for acquisition Pfizer Novozymes Unnamed pharma Ylanthia Totally new antibody platform Higher quality antibodies, greater diversity, better biophysical properties, faster lead generation Opens new opportunities 7

8 Innovative Product Pipeline 8

9 74 Therapeutic Antibody Programs in the Pipeline Program Gantenerumab MOR103 (2 programs) CNTO888 CNTO1959 (2 programs) BHQ880 BYM338 NOV 3 NOV 4 MOR208 MOR202 BAY BI 1 CNTO3157 CNTO 5 NOV 5 NOV 6 OMP-18R5 OMP-59R5 PFE 1 21 Programs, incl. 1 co-dev with NOV 32 Programs, incl. 1 co-dev with NOV Partner Roche Target Amyloid-ß Indication Discovery Preclinic Alzheimer s Disease Rheumatoid Arthritis GM-CSF Multiple sclerosis Janssen/J&J MCP-1 (CCL-2) IPF Psoriasis Janssen/J&J IL23p19 RA Novartis DKK-1 Cancer Novartis Musculoskeletal Novartis not discl. Novartis Ophthalmology CD19 CLL CD38 MM Bayer Healthcare Mesothelin (ADC) Cancer BI not discl. Janssen/J&J Asthma Janssen/J&J Inflammation Novartis Inflammation Novartis Cancer OncoMed Fzd 7 Cancer OncoMed Notch 2 Cancer Pfizer Cancer Various Partners - Various Indications Various Partners - Various Indications Phase 1 Phase 2 Phase 3 66 Partnered Programs 8 Proprietary Programs 9

10 Recent Partnered Pipeline Progress Gantenerumab Phase 2 trial expanded to potentially pivotal phase 2/3 CNTO1959 Comparison phase 2 study with Stelara in ~250 patients BYM338 Phase 2 in sporadic inclusion body myositis completed OMP-18R5 / OMP-59R5 Preclinical and clinical data presented at several scientific conferences BAY US orphan drug status in mesothelioma 10

11 Partner Program Case Study Gantenerumab: Alzheimer s Disease The Drug High affinity HuCAL antibody targeting amyloid-β Binds N-terminus and mid-section of Aβ40-42 peptide Large Market and Unmet Need AD is estimated to affect 25 million people worldwide High unmet medical need, no curative treatments available Clinical Development Phase 1, in patients: Completed Gantenerumab: Rapid, dose-dependent reduction of plaque: 16-36% reduction within 7 months Bapineuzumab: 9% plaque reduction over 18 months Pivotal Phase 2/3 Study Ongoing 770 prodromal patients, 2 doses, placebo-controlled 104 weeks on drug CDR-SOB, ADAS-COG, change in brain amyloid Favorable outcome to the trial could be used by Roche to support a marketing application 11

12 Recent Progress with Proprietary Portfolio MOR103 Data from completed phase 1b/2a in September 2012 Data for subcutaneous formulation Trial in MS ongoing MOR 208 Enrollment in phase 1 trial in CLL completed Study data expected in Q Presentation of preclinical combination therapy data at ASCO MOR202 Phase 1 trial in multiple myeloma ongoing 12

13 MOR103 A Novel Anti-Inflammatory Antibody The Drug Ultra-high affinity HuCAL IgG1 targeting GM-CSF GM-CSF is a key inflammatory mediator in rheumatoid arthritis and other inflammatory conditions Potential to become first and best-in-class anti-gm-csf mab Large Market and Unmet Need Revenues with approved biologics in rheumatoid arthritis over $12bn 50% of RA patients do not respond to anti-tnf therapy beyond 2 years Potential in MS, osteoarthritis, pain, asthma, COPD Intellectual Property Exclusive license to a US patent covering anti-gm-csf antibodies for the treatment of chronic inflammatory conditions US patent on MOR103 composition of matter 13

14 MOR103 A Novel Drug in a Clinically Validated Pathway Clinical Validation of Pathway Phase 2 data for mavrilimumab, antibody vs. GM-CSF receptor, provides clinical validation of the pathway in rheumatoid arthritis Clinical Development of MOR103 Phase 1, in healthy volunteers: MOR103 generally safe and well-tolerated Phase 1b/2a, in RA patients: Fully recruited, data expected in September 2012 Phase 1, PK study for sc administration: Initiated Q1 2012, data expected in September 2012 Phase1b, safety study in MS patients: Initiated Q4 2011, data expected in

15 MOR208 (XmAb5574) A Novel Anti-Cancer Antibody The Drug Humanized, high affinity anti-cd19 antibody Exclusive license from Xencor Antibody comprises a proprietary Xencor modification of the Fc part of the antibody leading to rapid and sustained B-cell depletion Large Market and Unmet Need High unmet medical need in NHL, CLL & ALL Revenues with approved drugs in B cell malignancies (CLL, NHL & ALL) exceed $5bn Relapsing patients have only limited treatment options In ALL no antibody therapy at all exists and current chemotherapy regimens are associated with very unfavorable safety profile 15

16 MOR208 (XmAb5574) A Highly Competitive Novel Antibody Clinical Validation of Pathway Phase 2 data for blinatumomab validate CD19 as target for B-cell malignancies MOR208 Has An Attractive Competitive Profile Expect convenient dosing schedule Straightforward manufacturing Potential for good safety profile Significantly increased ADCC compared to unmodified antibody Clinical Development Preclinical Data show synergistic effects on target cell killing in combination therapies with existing drugs Phase 1, in 30 relapsed or refractory CLL/SLL patients: Recruitment completed Data expected in Q Phase 2: Trials in B cell malignancies starting Q

17 MOR202 A Novel Antibody for Multiple Myeloma The Drug High affinity HuCAL antibody targeting CD38 Large Market and Unmet Need Revenues with approved drugs in MM exceed $2bn MM median survival is approximately 3-5 years Competitive Profile Preclinical data show strong synergy in combinations of MOR202 with Velcade or Revlimid Clinical Development Phase 1, in relapsed or refractory MM patients: ongoing Phase 2a, monotherapy extension Phase 1b, MOR202 + Velcade Phase 1b, MOR202 + Revlimid Up to 82 patients, at sites in Germany and Austria 17

18 AbD Serotec 18

19 AbD Serotec Segment Complements Therapeutic Business Research Activities Catalogue of 15,000+ products Stable and recurring cash flows Customers comprise universities, government bodies, life science companies Website, ecommerce HuCAL Diagnostic Applications Custom antibody generation Using proprietary technologies to deliver superior Dx antibodies Future upside via royalties Working with over 20 Dx companies 19

20 Strong Financials 20

21 Key Financials in million 2011 Guidance 2012 H Group Revenues Total Operating Expenses COGS Funded R&D Proprietary R&D (incl. technology development) 36.8 Sales, General & Administrative Expenses 24.6 EBIT 10.1 Cash & Marketable Securities and Interest-bearing Assignable Loans (at end of period) (1.9)

22 Shareholdings Shares issued: 23,252,972 (June 30, 2012) Treasury stock: 255,415 (June 30, 2012) 22

23 Milestones in 2012 Proprietary Portfolio MOR103 Phase 1b/2a data in RA MOR208 Phase 1 data in CLL MOR202 to continue enrollment in phase 1 trial in MM patients Partnered Pipeline Several phase 2 studies will complete in 2012* CNTO888 (Janssen Biotech, IPF) BHQ880 (Novartis, oncology) BYM338 (Novartis, musculoskeletal diseases) Novartis (n.d.) 1-3 new INDs Technology-driven alliances New diagnostic products from AbD Serotec * MorphoSys estimates based on publicly-available information 23

24 Thank You Dr. Claudia Gutjahr-Löser Head of Corporate Communications & IR Phone +49 (0)89 / Fax +49 (0)89 / investors@morphosys.com Dr. Simon Moroney Chief Executive Officer Phone +49 (0)89 / Fax +49 (0)89 / HuCAL, HuCAL GOLD, HuCAL PLATINUM, CysDisplay, RapMAT, aryla and Ylanthia and 100 billion high potentials are registered trademarks of MorphoSys AG Slonomics is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG.